In a fresh demonstration of science’s newfound ability to alter the basic units of human life, researchers at the Medical College of Wisconsin have turned the cells in human skin into those in the liver, work that opens new avenues for treating diseases of the liver without relying on organ transplants.
Professor and stem cell researcher Stephen A. Duncan and other scientists in his lab reported this week in the journal Hepatology that they have created reprogrammed mouse liver cells that were identical to those grown in nature and were able to integrate and grow alongside those in a mouse
International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
Image via Wikipedia
Whitehead Institute researchers have developed a novel method of removing potential cancer-causing genes during the reprogramming of skin cells from Parkinson’s disease patients into an embryonic-stem-cell-like state. Scientists were then able to use the resulting induced pluripotent stem (iPS) cells to derive dopamine-producing neurons, the cell type that degenerates in Parkinson’s disease patients.
The work marks the first time researchers have generated human iPS cells that have maintained their embryonic stem-cell-like properties after the removal of reprogramming genes. The findings are published in the March 6 edition of the journal Cell.
Removing the reprogramming genes is also important because
Storing your children’s umbilical stem cells in private banks for autologous use is a growing trend. But is it an evil marketing ploy, a useless precaution, or a winning strategy? The debate rages on, but perhaps a report in Newsweek could shift the balance in favor of this practice.
When he was 9 months old, Dallas Hextall was diagnosed with cerebral paralysis, a serious neural disorder caused by oxygen deprivation in the uterus or at birth. His parents consulted many neurologists, but according to them, he boy’s chances for a recovery were almost non-existant.
What are the differences between embryonic, adult and induced pluripotent stem cells? Where do the experts expect the next medical application will be for stem cells? Do stem cells promote regeneration? How are cell types interacting? How can induced pluripotent stem (iPS) cells revolutionize drug discovery? Can cell therapies be made into a viable business? How close are we to finding the right business model? Are investors interested in stem cells today? What is the political and ethical landscape like now that the Obama administration has taken over the White House?
This is the Episode 1 of the Stem Cell